The voltage-dependent anion channel 1 (VDAC1) antibody is a crucial tool for studying the function and regulation of VDAC1. a protein predominantly located in the outer mitochondrial membrane. VDAC1. also known as mitochondrial porin, forms a channel that regulates the passage of metabolites, ions, and nucleotides between the mitochondria and cytoplasm, playing a central role in energy metabolism, calcium signaling, and apoptosis. It interacts with proteins involved in mitochondrial dynamics, such as Bcl-2 family members and hexokinase, and is implicated in modulating mitochondrial permeability transition pore (mPTP) opening, a key event in programmed cell death.
VDAC1 antibodies are widely used in techniques like Western blotting, immunofluorescence, and immunoprecipitation to detect protein expression levels, subcellular localization, and protein-protein interactions. These antibodies help investigate VDAC1’s role in diseases, including cancer (e.g., metabolic reprogramming in tumors), neurodegenerative disorders (e.g., impaired mitochondrial function in Alzheimer’s or Parkinson’s), and cardiovascular conditions (e.g., ischemia-reperfusion injury). Additionally, they aid in exploring post-translational modifications (e.g., phosphorylation, acetylation) that regulate VDAC1 activity under stress or pathological conditions.
High specificity and validation are critical for VDAC1 antibodies due to homology among VDAC isoforms (VDAC1-3) and potential cross-reactivity. Researchers rely on these antibodies to dissect mitochondrial dysfunction mechanisms and evaluate therapeutic strategies targeting VDAC1 in disease models.